The evaluation of efficacy of topical use of Nigella cream (Nigella sativa oil-extract) in chonic hand eczema

The evaluation of efficacy of topical use of Nigella cream (Nigella sativa oil-extract) in comparison with topical use of 0.1% Betamethasone and Eucerin on the clinical severity and quality of life in patients with chonic hand eczema reffering to Loghman-e-Hakim and Shohada-e-Tajrish hospitals during the year 1388-1389

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201111266959N3

Enrollment

Registered

2012-01-11

Start date

2010-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hand eczema. Dermatitis, unspecified Eczema NOS

Interventions

Intervention 1: The nigella cream with eucerin base is made by a valid pharmacology company. For blinding the participants but not investigators, all three creams( Nigella, Betamethasone, eucerin as p

the amount of applied creams is estimated by Finger Tip Unit (FTU). Intervention 2: We use Eucerin as a creamy base for the nigella oil so we use eucerin as a placebo. The Eucerin cream will be

Treatment - Drugs

Placebo

The nigella cream with eucerin base is made by a valid pharmacology company. For blinding the participants but not investigators, all three creams( Nigella, Betamethasone, eucerin as placebo) will be

the amount of applied creams is estimated by Finger Tip Unit (FTU).

We use Eucerin as a creamy base for the nigella oil so we use eucerin as a placebo. The Eucerin cream will be prepared in tubes with the same weight and appearance to nigella cream tubes and r

We use Eucerin as a creamy base for the nigella oil so we use eucerin as a base for betamethasone cream too. The betamethasone cream will be prepared in tubes with the same weight and appearance to n

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: - age between 18-60 y/o - patients should be eager to participate in trial -patients should have chronic hand eczema that is confirmed by two dermatologist separetely Exclusion criteria: -pregnancy and lactation -application of topical drugs during previous two weeks -usage of systemic therapies such as corticosteroids and immunosupressive drugs and antibiotics during the past 4 weeks - localized hand infection -history of hand contact dermatitis due to topical drugs including herbal remedies

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: 2 weeks. Method of measurement: Dermatology Life Quality Index (DLQI).;Resolution of severity and intensity of lesions. Timepoint: 2 weeks. Method of measurement: Hand Eczema Severity Index (HECSI).	—

Secondary

Measure	Time frame
Irritant or allergic contact dermatitis. Timepoint: 4 weeks. Method of measurement: physician assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Barikbin

Skin research center of Shahid Beheshti university of medical sciences

b_barikbin@sbmu.ac.ir+98 21 2274 1507

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026